{"id":8403,"date":"2021-12-16T13:28:01","date_gmt":"2021-12-16T18:28:01","guid":{"rendered":"https:\/\/puyapeptide.net\/product\/lisiraglide-cas-320367-13-3-es-un-agonista-del-receptor-del-peptido-1-similar-al-glucagon-glp-1\/"},"modified":"2021-12-16T13:28:01","modified_gmt":"2021-12-16T18:28:01","slug":"lisiraglide-cas-320367-13-3-es-un-agonista-del-receptor-del-peptido-1-similar-al-glucagon-glp-1","status":"publish","type":"product","link":"https:\/\/puyapeptide.net\/es\/product\/lisiraglide-cas-320367-13-3-es-un-agonista-del-receptor-del-peptido-1-similar-al-glucagon-glp-1\/","title":{"rendered":"Lisiraglide CAS 320367-13-3 es un agonista del receptor del p\u00e9ptido 1 similar al glucag\u00f3n (GLP-1)"},"content":{"rendered":"

Lisiraglide CAS 320367-13-3 es un agonista del receptor del p\u00e9ptido 1 similar al glucag\u00f3n (GLP-1)<\/strong><\/h2>\n

Nombre del producto: Lixisenatide
\n Sin\u00f3nimos: Lixisenatide,> 98%; lixisenatide; Lixisenatide | Lixisenatide Acetate; Lixisenatide Acetate; Lixisenatide USP \/ EP \/ BP
\n CAS: 320367-13-3
\n MF: C215H347N61O65S
\n MW: 4858,53
\n EINECS:
\n Categor\u00edas de productos:
\n Archivo Mol: 320367-13-3.mol <\/p>\n

Lisiraglide es un p\u00e9ptido-1 similar al glucag\u00f3n (GLP-1) agonista del receptor, una hormona que ayuda a normalizar los niveles de az\u00facar en sangre. La seguridad y eficacia del f\u00e1rmaco se evaluaron en 10 ensayos cl\u00ednicos que inscribieron a un total de 5400 pacientes con diabetes tipo 2. En estos ensayos, la lisiramida se evalu\u00f3 tanto como monoterapia como en combinaci\u00f3n con otros medicamentos para la diabetes aprobados por la FDA, que incluyen metformina, sulfonilureas, pioglitazona e insulina basal. En estos ensayos, el uso de lisiramida mejor\u00f3 los niveles de hemoglobina glucosilada (un indicador de los niveles de glucosa en sangre). Adem\u00e1s, m\u00e1s de 6000 pacientes con diabetes tipo 2 en riesgo de enfermedad cardiovascular ateroscler\u00f3tica fueron tratados con lisiramida o placebo en el Cardiovascular Outcomes Trial. El uso de lisiramida en estos pacientes no aument\u00f3 el riesgo de eventos cardiovasculares adversos. Lisiragide no debe usarse para tratar a pacientes con diabetes tipo 1 o pacientes con aumento de cetonas u orina en la sangre (cetoacidosis diab\u00e9tica). Los efectos secundarios m\u00e1s comunes asociados con la lisiramida son n\u00e1useas, v\u00f3mitos, dolor de cabeza, diarrea y mareos. La hipoglucemia es otro efecto secundario com\u00fan en pacientes tratados con lisiramida y otros f\u00e1rmacos antidiab\u00e9ticos como sulfonilureas y \/ o cultivo basal. Adem\u00e1s, se han informado reacciones de hipersensibilidad graves (incluida la hipersensibilidad) en los ensayos cl\u00ednicos con Lisiragib. <\/p>\n

Lixisenatide es un f\u00e1rmaco que se utiliza actualmente para tratar la diabetes y tambi\u00e9n es un agonista del receptor de GLP-1. Lixisenatide (Lyxumia) fue aprobado para su comercializaci\u00f3n en Europa en 2013 y es un tratamiento diab\u00e9tico inyectable basado en Lixisenatide, que se administra una vez al d\u00eda, junto con otros medicamentos o insulina, para pacientes cuyos niveles de glucosa en sangre solo pueden controlarse con medicamentos. < &>
\n Nota de Lisiraglide CAS 320367-13-3<\/strong>
\n Para uso exclusivo en investigaci\u00f3n, no para uso humano<\/p>\n","protected":false},"excerpt":{"rendered":"

Nombre del producto: Lixisenatide
\n Acetate; Lixisenatide USP \/ EP \/ BP
\n CAS: 320367-13-3
\n MF: C215H347N61O65S
\n MW: 4858.53
\n Mol Archivo: 320367-13-3.mol<\/p>\n","protected":false},"featured_media":2111,"comment_status":"open","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[355,355,355],"product_tag":[1275],"class_list":{"0":"post-8403","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-peptido-de-la-diabetes","9":"product_tag-lisiraglide-cas-320367-13-3-is-a-glucagon-like-peptide-1-glp-1-receptor-agonist-es","10":"desktop-align-left","11":"tablet-align-left","12":"mobile-align-left","14":"first","15":"instock","16":"shipping-taxable","17":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/puyapeptide.net\/es\/wp-json\/wp\/v2\/product\/8403","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/puyapeptide.net\/es\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/puyapeptide.net\/es\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/es\/wp-json\/wp\/v2\/comments?post=8403"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/es\/wp-json\/wp\/v2\/media\/2111"}],"wp:attachment":[{"href":"https:\/\/puyapeptide.net\/es\/wp-json\/wp\/v2\/media?parent=8403"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/puyapeptide.net\/es\/wp-json\/wp\/v2\/product_brand?post=8403"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/puyapeptide.net\/es\/wp-json\/wp\/v2\/product_cat?post=8403"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/puyapeptide.net\/es\/wp-json\/wp\/v2\/product_tag?post=8403"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}